Evidence map›Paper›PMID 35096315›Full record

ArticleArchives of Razi Institute2021

Determination of Ferrous Oxide Nanoparticles Minimum Inhibitory Concentration against Local Virulent Bacterial Isolates.

M Al-Rawi, N H A L Al-Mudallal, A A Taha

Open access · greenAbstract read
In one paragraph

Article in Archives of Razi Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M Al-RawiDepartment of Medical Microbiology, College of Medicine, Al-Iraqia University, Baghdad, Iraq.
N H A L Al-MudallalDepartment of Medical Microbiology, College of Medicine, Al-Iraqia University, Baghdad, Iraq.
A A TahaDepartment of Applied Science, Division of Biotechnology, University of Technology, Baghdad, Iraq.
Iraqi University · IQUniversity of Technology - Iraq · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The improvement of multi-resistance properties of the bacterial pathogen has recently been discussed as an emerging issue. In this regard, iron oxide nanoparticles have attracted the researchers' attention due to their wide application in the realm of medicine. Iron oxide nanoparticles have a high specific surface area that enables them to interact with the bacterial surface structure and has considerable antibacterial activity. The current study aimed to synthesize a novel antimicrobial agent from iron oxide nanoparticles and determine its minimum inhibitory concentration (MIC) on different gram-positive and negative variant bacterial strains isolated and characterized from the infected urinary tract of Iraqi elderly patients. This study was conducted from September 2020 to December 2020 on 75 urine samples collected from the infected urinary tract of elderly patients in the ages range of 60-75 years admitted to Al-Yarmouk Medical Hospital, Baghdad, Iraq. Isolation of bacterial isolates was carried out using differential and selective media. Afterward, they were characterized and confirmed using different biochemical tests and VITEK 2 system, respectively. Magnetic nanoparticles were fabricated by co-precipitation of ferric ions (Fe

Indexed as

Anti-Bacterial AgentsEscherichia coliFerrous CompoundsNanoparticlesHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsFerrous Compoundsferrous oxideBacterial StrainsIron Oxide NPsMinimum inhibitory concentrationUTI Elderly Patients

Identifiers

PMID35096315
PMCPMC8790978
OpenAlexW3199682386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.